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Abstract
Introduction Perampanel is a first-in-class antiepileptic
drug approved for adjunctive treatment of partial-onset
seizure in patients aged 12 years or older. Published ran-
domised controlled trials (RCTs) had small sample sizes,
and meta-analyses have included too few studies to draw
conclusive results for the assessment of tolerability, effi-
cacy and safety of perampanel. There is a need to conduct a
meta-analysis with a larger dataset and an appropriate
study design.
Objective The aim of this study was to systematically
review the efficacy and safety of perampanel in the treat-
ment of partial-onset epilepsy.
Methods Electronic and clinical trials databases were
searched for RCTs of perampanel published up to March
2013. Outcomes of interest were 50 % responder rates,
seizure freedom, treatment-emergent adverse events (TE-
AEs) and incidence of withdrawal. Meta-analysis was
performed to investigate the outcomes of interest.
Results Five RCTs with a total of 1,678 subjects were
included. The 50 % responder rates were significantly
greater in patients receiving 4, 8 and 12 mg perampanel
versus placebo, with risk ratios of 1.54 (95 % CI
1.11–2.13), 1.80 (95 % CI 1.38–2.35) and 1.72 (95 % CI
1.17–2.52), respectively. There was no statistical evidence
of a difference in seizure freedom between 8 or 12 mg
perampanel and placebo. Of the five commonly reported
TEAEs included, both dizziness and somnolence were
statistically associated with 8 mg perampanel, whilst diz-
ziness was statistically associated with 12 mg perampanel.
Incidences of withdrawal due to adverse events were sig-
nificantly higher in the 8 mg and 12 mg perampanel groups
versus placebo.
Conclusion The use of perampanel resulted in a statisti-
cally significant reduction of seizure frequency with
respect to the 50 % responder rate in patients with partial-
onset epilepsy. Perampanel is well tolerated at 4 mg and
reasonably tolerated at 8 and 12 mg. Further clinical and
pharmacovigilance studies are required to investigate the
long-term efficacy and safety of perampanel in the man-
agement of other types of epilepsy.
1 Introduction
Epilepsy is a set of chronic neurological disorders involv-
ing a predisposition to generate seizures [1]. According to
the WHO, approximately 50 million people in the world
have epilepsy, and about 80 % of cases are found in
developing countries [2]. Pharmacological treatment is the
first-line intervention for partial-onset epilepsy. Antiepi-
leptic drugs (AEDs) that aim to suppress seizure occur-
rence have been widely used in epilepsy treatment. Clinical
guidelines have been issued for the management of epi-
lepsy [3, 4]. These guidelines suggest that the use of AEDs
should be personalised, and the choice of AEDs should be
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based on factors including the patient’s epilepsy syndrome,
seizure type and lifestyle. A variety of AEDs have been
designed to target different mechanisms involved in seizure
development. Common mechanisms of AEDs include the
blocking of sodium or calcium channels, activation of
potassium channels, enhancement of gamma aminobutyric
acid (GABA) activity and inhibition of excitatory amino
acids [5].
Perampanel is a highly selective and non-competitive
antagonist of the a-amino-3-hydroxy-5-methyl-4-iso-
xazolepropionic acid (AMPA) glutamate receptor [6].
AMPA receptors are found on the excitatory synapses in
the central nervous system [7]. These receptors mediate
fast synaptic signalling by the binding of glutamate, which
is an excitatory neurotransmitter. Overexpression of
AMPA receptors plays a crucial role in the forming and
spreading of seizures. Therefore, as an AMPA receptor
antagonist, perampanel produces an antiepileptic effect.
The European Medicines Agency (EMA) and the US FDA
approved perampanel under the trade name Fycompa in
July 2012 and October 2012, respectively [8]. It is a first-
in-class AED approved for adjunctive treatment of partial-
onset seizure in patients aged 12 years or older.
A meta-analysis study conducted by Gao et al. [9]
investigated the efficacy and safety of six AEDs, including
eslicarbazepine, retigabine (or ezogabine), carisbamate,
lacosamide, brivaracetam and perampanel. Gao et al.
assessed efficacy using the 50 % responder rate, and the
odds ratio (OR) of perampanel compared with placebo was
reported to be 1.79 (95 % CI 0.88–3.63; p = 0.11). Ran-
domised controlled trials (RCTs) of perampanel included
in the study by Gao et al. (labelled as study 206 and 208)
were designed to investigate tolerability, and therefore only
provided preliminary efficacy results [10]. The small
sample sizes in the two studies may not be sufficient to
obtain a conclusive result.
There is a need to conduct a meta-analysis with a larger
dataset and an appropriate study design. We conducted a
meta-analysis to combine evidence from currently avail-
able RCTs and further investigated the efficacy and safety
of perampanel. Two dose-escalation phase II studies
(labelled as studies 206 and 208) and three placebo-con-
trolled phase III studies (labelled as studies 304, 305 and
306) were included in our analysis [10–13].
2 Materials and Methods
This systematic review was conducted according to the
Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) statement [14]. The Cochrane
Library [Cochrane Central Register of Controlled Trials
(CENTRAL); Cochrane Database of Systematic Reviews;
and Cochrane Epilepsy Group Register], EMBASE and
PubMed electronic databases were used to perform the
literature search. The following search terms were used:
(perampanel) OR (Fycompa) OR (E2007). In order to
identify relevant potential studies, the following trial reg-
isters were used: the WHO International Clinical Trials
Registry Platform [ICTRP] (http://www.who.int/ictrp/en/),
the US National Institutes of Health Clinical Trials Reg-
istry (http://www.clinicaltrials.gov) and the metaRegister
of Controlled Trials [mRCT] (http://www.controlled-trials.
com). The search was performed on 11 March 2013. Titles,
abstracts and the content of the articles were screened to
determine whether the articles met the inclusion criteria.
The reference lists of the articles that met the inclusion
criteria were also screened to identify potentially relevant
studies. The searching workflow is shown in Fig. 1.
2.1 Inclusion Criteria
This meta-analysis includes published RCTs investigating
the efficacy and safety of perampanel in patients (aged
12 years or older) diagnosed with partial-onset seizure with
or without secondary generalisation. Partial-onset seizure
was defined according to the 1981 International League
Against Epilepsy Classification of Epileptic Seizures [15].
Since our meta-analysis aimed to investigate efficacy and
safety of perampanel as adjunctive therapy, all the included
studies targeted patients who were receiving one to three
AEDs prior to study commencement. Conference pro-
ceedings were excluded. There were no restrictions on
language. Full texts were evaluated for accessing the
inclusion criteria.
2.2 Outcome Measures
The primary outcome for measuring efficacy was the 50 %
responder rate, which is defined as the proportion of
patients who had a C50 % reduction of seizure frequency
in the maintenance period when comparing with baseline
[16]. Another outcome was seizure freedom. The ‘prag-
matic intent-to-treat (ITT)’ was used to define seizure
freedom in this meta-analysis. Seizure freedom is defined
as the proportion of seizure-free patients who completed
treatment through the maintenance period in the ITT
population [17].
Secondary outcomes were the number of patients who
experienced treatment-emergent adverse events (TEAEs).
A TEAE is an adverse event that occurred or became worse
during the treatment period. An adverse event was defined
as a TEAE if it arose within 30 days after the patient’s last
treatment date [11]. TEAEs assessed in this meta-analysis
included dizziness, fatigue, headache, somnolence and
nasopharyngitis. These TEAEs were assessed as they were
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the most common TEAEs in the included studies. Wors-
ening seizures were also investigated and are defined as a
[50 % increase in seizure frequency during the mainte-
nance period when compared with baseline. Another sec-
ondary outcome was the incidence of patient withdrawal
from treatment.
2.3 Data Extraction
YH performed the initial searches and screened abstracts
for eligibility. WQH and YH retrieved and screened full
texts of potential articles. The relevant articles were
assessed independently by both reviewers for inclusion in
the meta-analysis.
Primary and secondary outcome data were extracted
from all included studies by two independent reviewers,
CWS and WQH. The extracted data were cross-checked by
the two reviewers for data accuracy. Data on 50 %
responder rates, seizure freedom, TEAEs and withdrawal
were extracted from the eligible studies for the meta-
analysis. Non-statistical data extracted included author,
study location, study duration, perampanel dose, sample
size, number/type of concomitant AEDs and seizure type at
baseline.
2.4 Evaluation of Bias
The Cochrane Collaboration’s tool was used to assess the
risk of bias of the identified RCT articles [18] (Online
Resource Table 1). Assessment was conducted and cross-
checked by two independent reviewers (CWS and WQH).
Discrepancies were resolved by consensus.
2.5 Statistical Analysis
All the outcomes of interest (i.e. 50 % responder rates,
seizure freedom, withdrawal from trials and TEAEs) were
dichotomous. Risk ratios (RRs) were calculated for all the
outcomes. DerSimonian and Laird random-effects model
was used to account for heterogeneity between studies [19].
Studies 206 and 208 were designed to investigate tolera-
bility and safety of perampanel, while the other included
studies were designed to investigate efficacy and safety. It
may not be appropriate to use the fixed-effect model which
makes the assumption that the treatment effect in all the
included studies are identical [20]. Therefore, the random-
effects model was chosen. I2 statistic was calculated to
describe the proportion of the variability that was due to
heterogeneity rather than sampling error. ITT data were
Fig. 1 Review flowchart
(PRISMA flowchart)
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used in the efficacy analysis, and the safety population data
were used for the safety analysis. Publication bias was not
assessed using funnel plot as there were few included
studies. However, we were able to conduct a meta-analysis
as the included studies had a sufficiently large number of
patients. Review Manager 5.2 (Copenhagen: The Nordic
Cochrane Centre, The Cochrane Collaboration, 2013) was
used to carry out all statistical analyses.
3 Results
3.1 Search Results and Study Selection
Figure 1 summarises the review flowchart in accordance
with the PRISMA statement [14]. The electronic search in
the Cochrane Library, EMBASE and PubMed yielded a
total of 186 studies. No additional clinical trials on per-
ampanel use in patients with partial-onset epilepsy were
identified in the trial registers. After removing the duplicate
studies, the titles and abstracts of 146 records were
screened. Of these, 142 records were further removed since
they were not RCTs related to perampanel use in patients
with partial-onset epilepsy. Full texts of the four remaining
records were retrieved for detailed evaluation, and all were
included in this meta-analysis. As a result, four records
(with five studies since one record contained two studies)
were included in the meta-analysis, giving a total sample
size of 1678 (1176 for the perampanel group and 502 for
the placebo group). Tables 1 and 2 summarise the char-
acteristics of the included studies.
3.2 Methodological Quality
All the included studies were reported to be double-blind.
Methods of sequence generation and allocation conceal-
ment were reported in three studies. There were risks of
bias in all studies since some of the outcomes stated in the
trial protocol were not reported. In the included studies,
efficacy and safety data were reported with different doses
of perampanel. In this meta-analysis, studies were grouped
by dose groups and 50 % responder rates/seizure freedom
Table 1 Patient characteristics of randomised controlled trials included in this meta-analysis





























133 68 35.8 ± 14.2 1–3 282.8 ± 162.2 271 345 279
133 65 36.7 ± 14.6 279.5 ± 172.4
121 67 35.6 ± 14.7 289.6 ± 154.4






129 64 36.7 ± 14.4 1–3 270.3 ± 163.4 240 328 262
America 121 71 35.5 ± 14.1 255.9 ± 158.6
Europe 136 65 34.4 ± 13.6 264.2 ± 155.3






Europe 180 95 33.8 ± 13.6 1–3 232.4 ± 145.2 423 593 487
Asia 172 84 33.6 ± 12.2 236.9 ± 145.3
Australia 169 92 34.6 ± 12.8 239.4 ± 142.9
184 90 33.4 ± 12.6 209.9 ± 128.1




Australia 50 29 40.0 ± 11.38 1 or 2 301.2 ± 161.4 76 148 92
Europe 51 29 42.5 ± 12.06 276.0 ± 155.9
North
America
51 28 38.1 ± 11.62 274.8 ± 164.3




Australia 38 20 40.7 ± 11.99 1–3 267.6 ± 180.84 15 41 41
Europe 10 5 45.5 ± 12.05 216.0 ± 111.24
Total 48 Total 25
AEDs antiepileptic drugs, ITT intention-to-treat, SD standard deviation
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at each dose, with data from at least two studies reported in
the forest plot (Figs. 2 and 3). The responder rate at 2 mg
was only reported in one study (Online Resource Fig. 1).
The seizure freedom at 2 mg and 4 mg were also reported
in one study only (Online Resource Fig. 2).
The primary objective of studies 206 and 208 [10] was
to assess tolerability of different doses of perampanel,
while the other included studies [11–13] primarily assessed
efficacy. Studies 206 and 208 only reported overall efficacy
results, and did not report the individual dose subgroup
results. In the subgroup analysis, the two studies were
assigned to a dose group according to the maximum dose
tested in that study. Study 206 was assigned to the 4 mg
group since 82.4 % of the subjects were able to reach
4 mg. Study 208 was assigned to the 12 mg group. As only
37.5 % of subjects were able to reach 12 mg, sensitivity
analysis was conducted to investigate the effect of
removing and assigning study 208 to different dose groups.
3.3 Efficacy
The 50 % responder rates of patients with partial-onset
seizures receiving 4 mg, 8 mg and 12 mg perampanel were
investigated. The estimated RRs were 1.54 (95 % CI
1.11–2.13), 1.80 (95 % CI 1.38–2.35) and 1.72 (95 % CI
1.17–2.52) for the 4 mg, 8 mg and 12 mg groups, respec-
tively. This suggests that there was statistical evidence of
higher 50 % responder rates in patients receiving peram-
panel treatment in all three dose groups when compared with
the placebo group. For the seizure freedom, the estimated
RRs were 2.93 (95 % CI 0.99–8.71) and 3.60 (95 % CI
0.89–14.61) for the 8 mg and 12 mg groups, respectively.
The results suggest that there was no statistical evidence of a
difference in seizure freedom in the 8 mg or 12 mg peram-
panel groups when compared with the placebo group.
A 50 % responder rate with 2 mg perampanel was only
reported in one study. The RR was 1.15 with a 95 % CI of
0.75–1.75, which did not show evidence of a difference in
50 % responder rate when comparing 2 mg perampanel
with placebo. Seizure freedom at 2 mg and 4 mg peram-
panel were also not included in this meta-analysis due to
too few studies being available. The RRs were 1.53 (95 %
CI 0.26–9.07) and 3.74 (95 % CI 0.79–17.78) for the 2 mg
and 4 mg groups, respectively. There was no evidence of a
difference in seizure freedom when comparing 2 mg or
4 mg perampanel with placebo.
3.4 Safety
Table 3 shows the most commonly reported TEAEs. Diz-
ziness, somnolence, headache, fatigue and nasopharyngitis
were included in this meta-analysis. The association
between perampanel and TEAEs was assessed using 95 %
CIs of the RRs. There was no evidence of a statistically
significant association between the use of 4 mg perampanel
and the five TEAEs. In contrast, there was statistical evi-
dence of differences between use of 8 mg perampanel and
placebo in the incidences of dizziness/somnolence. The use
of 12 mg perampanel was also shown to be associated with
dizziness. In all the cases where evidence of association
existed, the risks of the TEAEs were higher in the per-
ampanel group when comparing with the placebo group. In
the 4 mg and 8 mg subgroups, the incidence of worsening
seizures was significantly lower with perampanel when
compared with placebo. In the 12 mg group, there was no
statistical difference between perampanel and placebo with
respect to the incidence of worsening seizures.
Patient withdrawal from the included trials was inves-
tigated and categorized into three groups (Table 3): with-
drawal due to any cause, adverse events or lack of
therapeutic effect. There was statistically significant evi-
dence of a higher incidence of withdrawal due to any cause
with the use of 12 mg perampanel when compared with
placebo. There was also evidence of a higher incidence of
withdrawal due to adverse events in patients receiving 8
mg or 12 mg perampanel when compared with those
patients receiving placebo. For withdrawal due to lack of
Table 2 Study design of randomised controlled trials included in this
meta-analysis
Article Study design Dosage of
perampanel
French et al. 2012 [11]
(study 304)
6 weeks baseline 8 mg QD
6 weeks titration 12 mg QD
13 weeks maintenance Placebo
4 weeks follow-up
French et al. 2013 [12]
(study 305)
6 weeks baseline 8 mg QD
6 weeks titration 12 mg QD
13 weeks maintenance Placebo
4 weeks follow-up
Krauss et al. 2012 [13]
(study 306)
6 weeks baseline 2 mg QD
6 weeks titration 4 mg QD
13 weeks maintenance 8 mg QD
4 weeks follow-up Placebo
Krauss et al. 2012 [10]
(study 206)
4 weeks baseline Maximum dose
of 2 mg BID
8 weeks titration Maximum dose
of 4 mg QD
4 weeks maintenance Placebo
2 weeks follow-up
Krauss et al. 2012 [10]
(study 208)
4 weeks baseline Maximum dose
of 12 mg QD
12 weeks titration Placebo
4 weeks maintenance
BID twice per day, QD once per day
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therapeutic effect, the RRs for 8 mg and 12 mg perampanel
compared with placebo were 0.57 (95 % CI 0.09–3.48) and
0.97 (95 % CI 0.20–4.76), respectively. No statistically
significant differences were observed between perampanel
and placebo in withdrawal due to lack of therapeutic effect.
3.5 Sensitivity Analysis
The effect of including study 208 [10] was tested by
moving it to the 4/8 mg subgroup and removing it from the
meta-analysis (Online Resource Table 2). Moving or
removing this study did not significantly alter the RRs of
50 % responder rate. For example, excluding study 208
from the meta-analysis only led to a change in RR in the 12
mg perampanel group from 1.72 (95 % CI 1.17–2.52) to
1.74 (95 % CI 1.04–2.90). Although excluding or moving
study 208 might lead to changes in heterogeneity (e.g.
excluding study 208 led to an increase of I2 statistic from
31 to 66 % in the 12 mg perampanel group), it did not
materially alter the estimations.
Fig. 2 Risk ratios of 50 % responder rates for different doses of perampanel. df degree of freedom, M–H Mantel–Haenszel
Fig. 3 Risk ratios of seizure freedom for 8 mg and 12 mg perampanel. df degree of freedom, M–H Mantel–Haenszel
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4 Discussion
The use of perampanel at doses of 4, 8 and 12 mg resulted
in statistically significant reductions in seizure frequency
with respect to the 50 % responder rate in patients with
partial-onset epilepsy compared with those treated with
placebo. Our meta-analysis showed that the withdrawal
rate due to any cause in the 12 mg perampanel group was
significantly higher than that of the placebo group with OR
of 2.03 (95 % CI 1.15–3.58). However, no statistically
significant differences were observed between 4 mg or
8 mg perampanel and placebo in withdrawal due to any
cause.
The previous meta-analysis of Gao et al. [9] did not
show statistical evidence of a difference between peram-
panel and placebo in reducing seizure frequency in terms of
50 % responder rate. It is likely due to the limited number
of studies available at the time of their meta-analysis. Our
meta-analysis included more patients and has sufficient
power to confirm the efficacy. Gao et al. also reported the
50 % responder rate ORs for eslicarbazepine, retigabine,
carisbamate, lacosamide and brivaracetam to be 2.43
(95 % CI 1.77–3.35), 2.81 (95 % CI 2.09–3.78), 1.49
(95 % CI 1.19–1.88), 2.11 (1.58–2.82) and 3.78 (95 % CI
1.73–8.26), respectively. Our results on 4, 8 and 12 mg
perampanel were all comparable with that results of Gao
et al. on the five individual AEDs, suggesting significantly
higher 50 % responder rates in the AEDs when compared
with placebo.
The individual ORs (treatment groups/placebo groups)
for withdrawal rates of eslicarbazepine, retigabine, cari-
sbamate, lacosamide and brivaracetam were 1.12 (95 % CI
0.71–1.79), 2.33 (95 % CI 1.56–3.45), 1.52 (95 % CI
0.78–2.94), 2.78 (95 % CI 1.39–5.56) and 0.29 (0.09–0.99)
in the study by Gao et al. Our results on 4 mg and 8 mg
perampanel were comparable with the results for es-
licarbazepine and carisbamate in the study by Gao et al.,
suggesting non-significant differences in withdrawal rate in
the AEDs when compared with placebo. On the other hand,
our result on the withdrawal rate due to any cause of 12 mg
perampanel was consistent with the ORs of Gao et al. for
retigabine and lacosamide, which showed significantly
higher withdrawal rates in the AED groups when compared
with placebo. In order to confirm the results and compare
perampanel with other AEDs, further head-to-head direct
comparison studies are needed.
Perampanel treatments at 4, 8 and 12 mg had all resulted
in higher 50 % responder rates compared with the placebo
group. A non-statistically significant dose-dependent effect
was observed. Comparing the three dose groups on the
forest plot (Fig. 2), the use of 8 mg perampanel appeared to
result in a slightly higher responder rate than when using
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when the dose reached 8 mg, as a difference could not be
observed when comparing 8 mg and 12 mg. The manu-
facturer of perampanel recommends a starting dose of
2 mg daily and a maximum daily dose of 12 mg as
adjunctive treatment of partial-onset seizure in patients
aged 12 years or older [21]. They also state in their pre-
scribing information that the use of a daily dose of 12 mg
may lead to a moderately improved reduction of seizure
frequency compared with the use of a daily 8 mg dose [21].
However, our study did not show any clear difference in
50 % responder rate when comparing the use of 8 mg and
12 mg perampanel.
Freedom from seizures is one of the main goals of AED
treatment. However, our meta-analysis did not demonstrate
a statistically significant improvement in seizure freedom
with 8 or 12 mg perampanel when compared with placebo.
This finding is consistent with that of the meta-analysis
conducted by Martyn-St James et al. [22] who also reported
a non-statistically significant improvement in seizure
freedom in patients treated with eslicarbazepine acetate,
lacosamide and tiagabine compared with patients treated
with placebo. These results probably reflected the fact that
the populations selected for the study by Martyn-St James
et al. and our included add-on clinical trials were patients
with difficult-to-treat epilepsy. All the patients recruited in
our included RCTs were patients with partial-onset epi-
lepsy despite being treated with at least two AEDs prior to
the baseline period. This suggests that the recruited patients
were likely to be drug resistant; therefore, the poor out-
come in seizure freedom was not unexpected.
Dizziness and somnolence are common adverse events
found in many AEDs [22, 23]. In the study by James et al.,
the AEDs eslicarbazepine acetate, lacosamide, pregabalin,
retigabine, tiagabine and zonisamide were statistically
associated with the increased incidence of dizziness com-
pared with placebo. Notably, there was a statistically sig-
nificant increase in the incidence of somnolence with
pregabalin, retigabine and zonisamide versus placebo. Our
meta-analysis demonstrated a statistically significant
increase in the incidence of dizziness for 8 mg or 12 mg
perampanel versus placebo. Our study also showed a sta-
tistically significant association between the use of 8 mg
perampanel and an increased incidence of somnolence. We
were not able to investigate rare adverse events since the
included studies only reported the common TEAEs. Fur-
thermore, rare adverse events may not be apparent in the
relatively small number of patients treated with perampanel
over such short follow-up periods.
Data for the use of 2 mg perampanel could only be
found in study 306 [13], and it was not included in the
meta-analysis. Based on data from study 306 only, the RR
for 50 % responder rate was calculated to be 1.15 (95 % CI
0.75–1.75). There was no evidence of a statistically
significant association between the use of 2 mg perampanel
and a change in the 50 % responder rate. RRs were also
calculated for the TEAEs and withdrawal rates, and there
was no statistical evidence of an association between the
use of 2 mg perampanel and the incidence of withdrawal
for the five commonly reported TEAEs (dizziness, som-
nolence, headache, fatigue and nasopharyngitis).
Our study included all relevant published RCTs inves-
tigating perampanel to date. No unpublished or ongoing
RCTs on perampanel treatment for patients with partial-
onset epilepsy were identified in the three trial registers;
therefore, it is reasonable to assume that the results of our
meta-analysis are unlikely to change in the foreseeable
future. Data extraction and statistical analysis were carried
out by independent reviewers and carefully cross-
checked.Several potential study limitations are worthy of
mention. Firstly, the number of studies and RCTs exploring
perampanel was relatively small. Only five studies were
included in this meta-analysis and all were pharmaceutical
company funded.
The second limitation was the inclusion of studies 206
and 208, which were relatively different from those others
included in terms of design and data presentation. The
reported responder rates in studies 206 and 208 were cal-
culated using pooled data across different dose groups,
while the other included studies reported responder rates
independently for each dose group. Despite this, the sen-
sitivity analysis showed that the overall conclusions were
not materially altered by removing or moving study 208.
Traditionally, newly-marketed AEDs are evaluated in
patients with severe epilepsy as on-add treatments for
short-term RCTs. Perampanel is no exception and we were
only able to identify add-on trials. Consequently, we were
not able to identify RCTs that evaluated perampanel as a
monotherapy or long-term treatment. We identified one
extension study (307) which involved patients from three
of the included studies (namely 304, 305 and 306). Study
307 investigated the long-term effect of perampanel [24];
however, it was not included in our analysis as it was an
open-label study targeting patients who had already par-
ticipated in those included studies. Nevertheless, study 307
reported that tolerability and efficacy of perampanel were
maintained in the long term. Further long-term RCTs with
newly diagnosed patients will be useful in studying the
long-term effect of perampanel.
Lastly, it is worthy to note that the common outcome
measures in short-term clinical trials investigating epilepsy
include 50 % seizure reduction, mean seizure reduction
and short-term tolerability. Such parameters are tradition-
ally designed for regulatory purposes. These trials do not
provide the impact of the new drugs on mortality and
morbidity rates, and often do not report the proportion of
patients becoming seizure free [25]. Other important
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outcomes including ‘time to treatment failure’, ‘time to
achieve a 12-month remission of seizures’, quality of life
outcomes and health economic outcomes are also used in
clinical trials [26]. Future clinical and pharmacoepidemi-
ological studies should be conducted to evaluate the real-
life clinical use and define the roles of each new AED in
the pragmatic setting [27, 28].
5 Conclusion
This meta-analysis showed that the use of perampanel
resulted in a statistically significant reduction of seizure
frequency with respect to the 50 % responder rate when
compared with placebo. The safety analysis showed that
perampanel was well tolerated at 4 mg and reasonably
tolerated at 8 and 12 mg. Further clinical and pharmaco-
vigilance studies will be needed to investigate the long-
term efficacy and safety of perampanel and, specifically,
the efficacy of perampanel in the management of other
types of epilepsy.
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